[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363578-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363578-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","inhibition-of-trpc6-channel-suppresses-bladder-cancer-proliferation-by-disrupting-store-operated-calcium-entry","Inhibition of TRPC6 channel suppresses bladder cancer proliferation by disrupting store-operated calcium entry","","TRPC6 channel inhibition is investigated as a strategy to suppress bladder cancer proliferation through interference with store-operated calcium entry (SOCE). TRPC6 expression is assessed in paired cancer and adjacent normal tissues, followed by KEGG enrichment and Ca2+ imaging to characterize TRPC6-dependent calcium signaling in cancer cells. SAR7334 and the SOCE antagonist MRS1845 reduce proliferation, with reduced activation of the PI3K/Akt/mTOR pathway. In contrast, the Akt inhibitor MK2206 does not alter SOCE, indicating SOCE as the upstream target.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/inhibition-of-trpc6-channel-suppresses-bladder-cancer-proliferation-by-disrupting-store-operated-calcium-entry/363578/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/inhibition-of-trpc6-channel-suppresses-bladder-cancer-proliferation-by-disrupting-store-operated-calcium-entry/363578.png","ImageObject",300,407,{"name":42,"@type":43},"Elsa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main finding about TRPC6 in bladder cancer cells?","Question",{"text":63,"@type":64},"TRPC6 is overexpressed in bladder cancer tissues and is associated with poor overall survival. Pharmacological inhibition of TRPC6 suppresses bladder cancer cell proliferation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do SAR7334 and MRS1845 affect bladder cancer proliferation?",{"text":68,"@type":64},"The TRPC6-specific antagonist SAR7334 significantly inhibits proliferation, and the SOCE-specific antagonist MRS1845 produces similar inhibitory effects.",{"name":70,"@type":61,"acceptedAnswer":71},"What signaling pathway is linked to TRPC6 inhibition?",{"text":72,"@type":64},"TRPC6 inhibition disrupts SOCE and leads to decreased activation of the PI3K/Akt/mTOR pathway, evidenced by reduced phosphorylation of PI3K, Akt, and phosphorylated mTOR.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363578,1790197021,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nInhibition ofTRPC6 channel suppresses bladder cancer proliferation by disrupting storeoperated calcium entry  \nJinhui Zha1,2,3,6, Xiaotong Guo2,3,6, Wentao Liao1,2,3,6, Peitao Wu2,3, YuhongWu2,3, Yingyue Guo2,3, Weifeng Yang4,5􀀍 & Li Gao1􀀍  \nDespite its prevalence, bladder cancer (BC) remains an unsolved pathogenesis. It is believed that TRPC6 channels have unique electrophysiological properties that contribute to intracellular Ca2+ signalling and tumorigenesis in cells. However, the mechanism by which TRPC6 contributes to BC progression and intracellular Ca2+ homeostasis remains unclear. In this study, TRPC6 expressions in paired BC and adjacent normal tissues were measured by immunohistochemistry. A KEGG pathway enrichment analysis was conducted to determine TRPC6’s potential contribution to BC. Ca2+ imaging analysis was performed to explore the contribution ofTRPC6 in the BC cell. Flow cytometry and Cell Counting Kit-8 assay were performed to explore the effects ofTRPC6 on the proliferation of BC. The impacts ofTRPC6 SOCE on PI3K/Akt/mTOR pathway were measured by western blot. Based on the above bunch of studies, TRPC6 was found to be overexpressed in human BC tissue, which correlated with poor survival rates for patient overall survival (OS). We used the TRPC6-specific antagonist SAR7334 to explore and reveal significant inhibition of BC cell proliferation. Mechanistically, TRPC6 mediated cytosolicCa2+ and regulation of SOCE, leading to the activation of the IP3K/AKT/mTOR pathway. We found that SAR7334 arrested the phosphorylation of PI3K andAkt, thus causing a significant decrease in phosphorylated mTOR. Similar effects were observed for the SOCE-specific antagonist MRS1845 . In contrast, theAkt inhibitor MK2206 did not alter the SOCE in BC cells. Our results indicate that the pharmacological inhibition ofTRPC6 arrests tumour cell proliferation through SOCE targeting the PI3K/Akt/mTOR pathway.  \nKeywords Transient receptor potential canonical type 6, Bladder cancer, Store-operated calcium entry, PI3K/Akt pathway, Proliferation  \nBladder cancer (BC) is a large societal burden, with over 430,000 men and women diagnosed worldwide every year1–3. A key part of BC treatment is chemotherapy, especially for patients with non-muscle invasive BC. The use of intravenous chemotherapy after transurethral resection of BC can significantly reduce recurrence events and improve patient outcomes3. Even though chemotherapy and surgery have greatly improved the health of patients, the incidence and recurrence rates of BC remain high. It is important to explore the mechanism of tumorigenesis to BC and to find new anti-tumour drugs for the clinical treatment of BC.  \nThe Ca2+ signalling pathway plays a major role in physiological and pathological cellular responses, such as gene expression, cell proliferation, migration, and invasion, which may contribute to cancer development4. Intracellular Ca2+ is tightly regulated by influx/efflux mechanisms via ion channels, ATPase pumps, and exchangers, maintaining low intracellular Ca2+ levels to achieve homeostasis5,6. In advanced cancer cells, altered Ca2+ flux leads to hypercalcemia and aberrant calcium signalling7. In these cases, transient receptor potential (TRP) channel is one of the pathways for calcium influx into cells, and channel activation leads to  \n1Department of Urology, The Second Affiliated Hospital of Guilin Medical University, Guilin 541000, China. 2Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin 541199, Guangxi, China. 3Guangxi Health Commission Key Laboratory of Tumor Immunology and Receptor-Targeted Drug Basic Research, Guilin Medical University, Guilin 541199, Guangxi, China. 4Department of Urology, Shenzhen Nanshan People’s Hospital, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen 518052, China.  \n5Department of Urology, Qianhai She","cbCaii05JDww8yvM","https://ap.wps.com/l/cbCaii05JDww8yvM","pdf",2749229,13,"English","# Background\n## Bladder cancer burden and treatment\n## Ca2+ signaling and cancer\n# TRPC6 and SOCE Mechanistic Rationale\n## TRP channels and TRPC6 in tumor progression\n## ORAI/STIM-mediated SOCE\n# Experimental Approach\n## Tissue expression analysis and pathway enrichment\n## Ca2+ imaging\n## Cell proliferation assays and flow cytometry\n## Western blot for PI3K/Akt/mTOR signaling\n# Results and Interpretation\n## TRPC6 overexpression and poor survival correlation\n## Effects of SAR7334 and MRS1845 on proliferation\n## SOCE dependence and pathway activation changes\n## Role of Akt inhibitor MK2206","[{\"question\":\"What is the main finding about TRPC6 in bladder cancer cells?\",\"answer\":\"TRPC6 is overexpressed in bladder cancer tissues and is associated with poor overall survival. Pharmacological inhibition of TRPC6 suppresses bladder cancer cell proliferation.\"},{\"question\":\"How do SAR7334 and MRS1845 affect bladder cancer proliferation?\",\"answer\":\"The TRPC6-specific antagonist SAR7334 significantly inhibits proliferation, and the SOCE-specific antagonist MRS1845 produces similar inhibitory effects.\"},{\"question\":\"What signaling pathway is linked to TRPC6 inhibition?\",\"answer\":\"TRPC6 inhibition disrupts SOCE and leads to decreased activation of the PI3K/Akt/mTOR pathway, evidenced by reduced phosphorylation of PI3K, Akt, and phosphorylated mTOR.\"}]","Inhibition of TRPC6 channel suppresses bladder cancer proliferation by disrupting store-operated calcium entry | PDF",1790151918,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d36d98f8770b69ffd9f00e037e649cc.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05d9fb830dbe7d66964cbbbe1e853811.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da23add044af524323c4efa33aa3481b.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa5021726daf9c8d8202202ce75db617.webp",980,1287]